Cargando…

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension

Treprostinil is a chemically stable analog of prostacyclin, and inhaled treprostinil was developed to deliver the effects directly to the pulmonary vasculature while minimizing systemic side effects. The objective of the study was to evaluate the efficacy on hemodynamics and exercise capacity, safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuwana, Masataka, Abe, Kohtaro, Kinoshita, Hideyuki, Matsubara, Hiromi, Minatsuki, Shun, Murohara, Toyoaki, Sakao, Seiichiro, Shirai, Yuichiro, Tahara, Nobuhiro, Tsujino, Ichizo, Takahashi, Kenta, Kanda, Shingo, Ogo, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906001/ https://www.ncbi.nlm.nih.gov/pubmed/36788940 http://dx.doi.org/10.1002/pul2.12198

Ejemplares similares

Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)
por: Tamura, Yuichi, et al.
Publicado: (2021)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

SATISFY‐JP, a phase II multicenter open‐label study on Satralizumab, an anti‐IL‐6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune‐responsive‐phenotype: Study protocol
por: Tamura, Yuichi, et al.
Publicado: (2023)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy
por: Adachi, Shiro, et al.
Publicado: (2022)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Effect of Body Mass Index on Posttonsillectomy Hemorrhage
por: Hoshino, Tetsuro, et al.
Publicado: (2017)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That’s the Question
por: Jin, Qi, et al.
Publicado: (2022)

Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis
por: Sakao, Seiichiro, et al.
Publicado: (2019)

Treprostinil stimulates the engraftment of haematopoetic stem cells
por: Hussain, Filza, et al.
Publicado: (2011)

Successful management of an inadvertent excessive treprostinil overdose
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013)

Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertension　― Multicenter Study in Japan ―
por: Takeyasu, Rika, et al.
Publicado: (2020)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial
por: Hosokawa, Kazuya, et al.
Publicado: (2022)

Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation
por: Kazemi, Zahra, et al.
Publicado: (2016)

Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention
por: Ishii, Hideki, et al.
Publicado: (2008)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

Dosing characteristics of oral treprostinil in real-world clinical practice
por: Balasubramanian, Vijay P., et al.
Publicado: (2018)

Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome
por: Themanns, Madeleine, et al.
Publicado: (2018)

Oral treprostinil use in children: a multicenter, observational experience
por: Kanaan, Usama, et al.
Publicado: (2019)

An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
por: Hill, Nicholas S., et al.
Publicado: (2020)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
por: Alissa, Ibrahim, et al.
Publicado: (2023)

Determinants of an elevated pulmonary arterial pressure in patients with pulmonary arterial hypertension
por: Sakao, Seiichiro, et al.
Publicado: (2015)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
por: Kumar, Parag, et al.
Publicado: (2016)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4u021sskjglvc8q6coln4m2npe